The directors of Proteome Sciences are pleased to announce that at the Company's AGM, held at 2.30 p.m. today, all resolutions were duly passed.
A copy of the presentation given by the CEO, Jeremy Haigh, at the AGM will be available on the Company’s website tomorrow. Link here to AGM slides
At the Company’s AGM being held today at 2.30 pm the Chairman, Christopher Pearce, will make the following statement:
“As indicated in our recent results, we remain optimistic about the future, with the near-term availability of higher-plex TMT® set to add significant value to this asset, and the utility of quantitative proteomics increasing in response to diagnostic advances and disruptive technologies. We are pleased to report a good first quarter, with further growth in sales and royalties from TMT® and an improving services business continuing the trend in orders and revenues established during the latter part of 2018.”
The Annual Report and Accounts for the year ended 31 December 2018, together with a notice of the Annual General Meeting is available to view on the Companies website www.proteomics.com and will be posted to shareholders imminently.
The Company is pleased to announce its audited results for the year ended 31 December 2018.
The Directors of Proteome Sciences look forward to updating shareholders on the Company’s performance, and on the outlook for 2019, at the time of announcing the 2018 full year results which are scheduled for release on 2 April 2019.
Annual General Meeting
The Annual General Meeting of the Company will take place at the offices of Allenby Capital, 5 St Helen's Place, London EC3A 6AB, at 2.30pm on 30 April 2019. Formal notice of such will be posted to shareholders with the annual report in April.
A further non-exclusive licence to the Company’s stroke biomarker patent portfolio was completed on 22 January 2019 with Galaxy CCRO Inc. (“Galaxy”), a recently formed US clinical contract research organisation, which intends to develop a point of care test for the diagnosis and timing of stroke onset in order to direct patients to specialists who can administer thrombolytic treatment. Under the terms of the licence Proteome Sciences will receive equity in Galaxy as an initial licence fee, with subsequent development milestones and a running royalty on product sales. Galaxy CCRO Inc announcement
The Company today provides a trading update for the financial year ending 31 December 2018.
Unaudited revenues for the full year decreased by 11% to approximately £3.0m (2017: £3.4m). TMT® sales and royalties accounted for approximately £2.1m, reflecting a greater than 10% growth in that underlying business, while revenues from proteomics services were below expectations as a result of a weak first half of the year. Costs of £4.4m were 12% lower than the previous year (2017: £5.0m) reflecting the ongoing impact of consolidation and restructuring performed in 2017/2018. The Company anticipates a significantly reduced loss after tax of approximately £1.4m (2017: £2.5m) for the year.
Jeremy Haigh, Chief Executive of Proteome Sciences, commented: “As predicted, the fourth quarter of 2018 was the strongest for our proteomics services business, during which we recognised about 40% of our annual service revenues and generated work orders to the value of £0.25m.
The Board of Proteome Sciences plc is pleased to announce that Allenby Capital Limited has been appointed as the Company’s new Nominated Adviser and sole Broker with immediate effect.
Holdings in Company - TR1 notification was received from Spreadex Limited.
The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 23 November 2018 it purchased 1,000,000 Ordinary Shares of 1p in the capital of the Company ("Ordinary Shares") at 3.16p per Ordinary Share (the “Purchase”). Following the purchase, Vulpes has a total direct and indirect interest in 64,946,734 equivalent to 22% of Proteome Sciences' total issued share capital.